Gilead Sciences Inc at Cowen Virtual Oncology Innovation Summit Transcript
Good afternoon, and welcome once again to Cowen and Company's Second Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Gilead Sciences. We're really happy to have with us today, Merdad Parsey, the Chief Medical Officer of Gilead.
Merdad, thanks so much for joining us. I'm sure these are incredibly busy times for you.
I really appreciate the invite, Phil. Good to see you. Thanks.
Questions & Answers
I think we'll focus today's discussion specifically on your oncology pipeline in light of ASCO and EHA coming up. Maybe first, we'll start with Trodelvy. There's a vigorous debate on the Street about Trodelvy's TROPiCS-02 trial and ER-positive HER2
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
